F2 Ventures

ReNAgade Therapeutics is a biotechnology company specializing in RNA therapeutics aimed at treating various diseases. The company has developed a comprehensive RNA platform that facilitates coding, editing, and gene insertion, thereby enabling the creation of innovative medications. Utilizing a proprietary CRISPR-Cas9 system, ReNAgade’s technology allows for precise gene editing, which minimizes off-target effects and enhances the long-term efficacy of gene therapies. This approach positions the company to address a wide range of applications within the gene therapy landscape, ultimately making treatments safer and more effective for patients.

4M Analytics is a geo-data company specializing in subsurface infrastructure mapping. It has developed a sophisticated mapping engine that serves utility and infrastructure construction projects, particularly during the pre-planning and planning phases. This technology leverages artificial intelligence and analytics to analyze satellite and aerial imagery, allowing for the creation of detailed and accurate subsurface infrastructure maps. These maps can be generated remotely and do not require prior as-built data, making it possible to provide insights anywhere in the world at an unprecedented scale and low cost. The company's platform enhances location intelligence by identifying both known and unknown utilities or infrastructure, thereby maximizing efficiency and reducing the risks of delays, budget overruns, and safety issues in construction projects.

AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. The company's lead product, Viralym-M, targets multiple viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Additionally, AlloVir is advancing several product candidates through preclinical and clinical stages, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. The company, originally founded in 2013 as ViraCyte, Inc., rebranded to AlloVir in May 2019 and is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases.

Justt is a company that specializes in chargeback mitigation solutions for eCommerce merchants. It has developed an automated platform that utilizes artificial intelligence technology to combat illegitimate chargebacks. This platform is designed to streamline the process for merchants by offering an intuitive user dashboard, allowing them to easily track the status of their chargebacks. By leveraging this technology, Justt enables businesses to implement effective strategies to recover lost funds resulting from chargebacks.

Five Sigma LTD. is a technology company based in Tel Aviv-Yafo, Israel, that specializes in developing cloud-based software solutions for the insurance industry. Founded in 2017, the company offers a data-driven Claims Management Solution (CMS) that incorporates artificial intelligence and machine learning to streamline and automate the claims management process. Five Sigma's platform enhances decision-making for insurance adjusters by providing smart recommendations, automating workflows, and utilizing data modeling to minimize errors. It is designed for various users in the insurance sector, including leading insurance carriers, Insurtech firms, third-party administrators, and self-insured companies. By modernizing claims operations, Five Sigma aims to reduce claims leakage, enhance compliance, and improve overall customer experience.

4M Analytics is a geo-data company specializing in subsurface infrastructure mapping. It has developed a sophisticated mapping engine that serves utility and infrastructure construction projects, particularly during the pre-planning and planning phases. This technology leverages artificial intelligence and analytics to analyze satellite and aerial imagery, allowing for the creation of detailed and accurate subsurface infrastructure maps. These maps can be generated remotely and do not require prior as-built data, making it possible to provide insights anywhere in the world at an unprecedented scale and low cost. The company's platform enhances location intelligence by identifying both known and unknown utilities or infrastructure, thereby maximizing efficiency and reducing the risks of delays, budget overruns, and safety issues in construction projects.

Orna Therapeutics, founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, is a biotechnology company specializing in the development of fully engineered circular RNA therapeutics. The company's proprietary platform combines innovative technology to create circular RNAs that drive protein expression, coupled with validated delivery solutions. This approach aims to simplify production, enhance formula stability, and improve protein expression for treating various diseases.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. The company's lead product, Viralym-M, targets multiple viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Additionally, AlloVir is advancing several product candidates through preclinical and clinical stages, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. The company, originally founded in 2013 as ViraCyte, Inc., rebranded to AlloVir in May 2019 and is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases.

TriNetX, Inc. operates a global health research network that facilitates clinical research and enhances the discovery of new therapies. The company provides a suite of tools, including TriNetX Live for analyzing patient populations, TriNetX Research for accessing longitudinal clinical data, and TriNetX Download for obtaining real-world clinical data through a unified platform. Additionally, TriNetX offers Attract Trials to streamline collaboration, Natural Language Processing to extract clinical information from physician notes, and specialized oncology solutions to link researchers with clinical and genomic data. Serving healthcare organizations, biopharmaceutical companies, and contract research organizations, TriNetX aims to optimize clinical trial design and recruitment, improving the speed and efficiency of bringing new therapies to market. Established in 2013, the company is headquartered in Cambridge, Massachusetts, with additional offices in Sydney, London, and Sao Paulo.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focuses on developing novel T cell receptor therapies for cancer treatment. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 specializes in engineering T cells to target specific antigens expressed by cancer cells. The company's lead product candidates include TC-210, which targets mesothelin-positive solid tumors such as non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110, targeting CD19-positive B-cell hematological malignancies. TCR2's pipeline also includes candidates for adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company's approach is distinct from traditional CAR-T cells and other engineered T cell therapies, leveraging a deep understanding of T cell receptor biology to create highly differentiated treatments.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focuses on developing novel T cell receptor therapies for cancer treatment. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 specializes in engineering T cells to target specific antigens expressed by cancer cells. The company's lead product candidates include TC-210, which targets mesothelin-positive solid tumors such as non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110, targeting CD19-positive B-cell hematological malignancies. TCR2's pipeline also includes candidates for adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company's approach is distinct from traditional CAR-T cells and other engineered T cell therapies, leveraging a deep understanding of T cell receptor biology to create highly differentiated treatments.

iPrice Group is an online price comparison platform that aims to enhance the e-commerce experience for shoppers in Southeast Asia by offering a diverse selection of products from numerous online retailers. The company provides users with the ability to compare prices, discover various products, and find the best deals across multiple categories, including electronics, fashion, home improvements, and baby products. By partnering with hundreds of online shops, iPrice facilitates a transparent and convenient shopping experience. Established in Kuala Lumpur, the company has rapidly expanded its presence across seven markets, including Indonesia, Vietnam, Singapore, Hong Kong, Thailand, and the Philippines. With a mission to boost trust and convenience in the e-commerce sector, iPrice leverages international expertise in technology and online marketing to serve its customers effectively.

Clinical Ink, Inc. specializes in providing eSource and patient engagement solutions designed to streamline clinical research for sites, sponsors, contract research organizations (CROs), and patients. Founded in 2006 and headquartered in Horsham, Pennsylvania, with additional offices in Winston-Salem and Cary, North Carolina, Philadelphia, Pennsylvania, and Cambridge, Massachusetts, the company offers a suite of innovative tools including SureSource, an electronic source platform that captures data and documents at the site level, and Lunexis ePRO+, which facilitates patient participation in studies. Additionally, Clinical Ink provides CentrosHealth, a patient engagement platform that includes configurable apps to enhance patient involvement and compliance throughout clinical trials. The company aims to improve clinical trial workflows by integrating electronic data capture and reducing manual processes, ensuring that clients have access to high-quality, validated data.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, established in 2001. The company specializes in developing oral medications using its proprietary Transient Permeability Enhancer technology, which allows for the conversion of injectable drugs to oral formulations. This platform not only enhances drug absorption but also enables the exploration of new indications for existing therapies. Chiasma's primary product is MYCAPSSA, an oral formulation of octreotide capsules designed for the treatment of acromegaly, a condition characterized by excessive production of growth hormone. Currently, MYCAPSSA is undergoing Phase III clinical trials in the United States and is also being developed for regulatory approval in the European Union, targeting adult patients with this rare and serious condition.

ProterixBio, Inc. is a biomedical company based in Billerica, Massachusetts, focused on developing disease management platforms for chronic respiratory diseases. The company specializes in proprietary blood-based biomarker tests aimed at transforming the management of conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. ProterixBio's ViBE platform, along with its Acoustic Membrane MicroParticle (AMMP) assays, facilitates the precise analysis of proteins in various sample types, delivering real-time biological assessments of a patient's disease state. This technological innovation enhances the sensitivity and specificity of traditional testing methods, allowing healthcare providers to make informed decisions that help reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. Founded in 2002, ProterixBio seeks to address the unmet needs in chronic care management through its advanced diagnostic capabilities.

ProterixBio, Inc. is a biomedical company based in Billerica, Massachusetts, focused on developing disease management platforms for chronic respiratory diseases. The company specializes in proprietary blood-based biomarker tests aimed at transforming the management of conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. ProterixBio's ViBE platform, along with its Acoustic Membrane MicroParticle (AMMP) assays, facilitates the precise analysis of proteins in various sample types, delivering real-time biological assessments of a patient's disease state. This technological innovation enhances the sensitivity and specificity of traditional testing methods, allowing healthcare providers to make informed decisions that help reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. Founded in 2002, ProterixBio seeks to address the unmet needs in chronic care management through its advanced diagnostic capabilities.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, established in 2001. The company specializes in developing oral medications using its proprietary Transient Permeability Enhancer technology, which allows for the conversion of injectable drugs to oral formulations. This platform not only enhances drug absorption but also enables the exploration of new indications for existing therapies. Chiasma's primary product is MYCAPSSA, an oral formulation of octreotide capsules designed for the treatment of acromegaly, a condition characterized by excessive production of growth hormone. Currently, MYCAPSSA is undergoing Phase III clinical trials in the United States and is also being developed for regulatory approval in the European Union, targeting adult patients with this rare and serious condition.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, established in 2001. The company specializes in developing oral medications using its proprietary Transient Permeability Enhancer technology, which allows for the conversion of injectable drugs to oral formulations. This platform not only enhances drug absorption but also enables the exploration of new indications for existing therapies. Chiasma's primary product is MYCAPSSA, an oral formulation of octreotide capsules designed for the treatment of acromegaly, a condition characterized by excessive production of growth hormone. Currently, MYCAPSSA is undergoing Phase III clinical trials in the United States and is also being developed for regulatory approval in the European Union, targeting adult patients with this rare and serious condition.

ProterixBio, Inc. is a biomedical company based in Billerica, Massachusetts, focused on developing disease management platforms for chronic respiratory diseases. The company specializes in proprietary blood-based biomarker tests aimed at transforming the management of conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. ProterixBio's ViBE platform, along with its Acoustic Membrane MicroParticle (AMMP) assays, facilitates the precise analysis of proteins in various sample types, delivering real-time biological assessments of a patient's disease state. This technological innovation enhances the sensitivity and specificity of traditional testing methods, allowing healthcare providers to make informed decisions that help reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. Founded in 2002, ProterixBio seeks to address the unmet needs in chronic care management through its advanced diagnostic capabilities.